Trial Profile

Early phase 2 study to investigate the efficacy and safety of AKP-009 in patients with benign prostatic hyperplasia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AKP 009 (Primary)
Indications Benign prostatic hyperplasia
Focus Therapeutic Use
Sponsors ASKA Pharmaceutical

Most Recent Events

05 Oct 2020 New trial record
30 Sep 2020 According to a ASKA Pharmaceutical media release, ASKA and KYORIN have entered into a joint development and commercialization agreement regarding, a treatment agent for Benign Prostatic Hyperplasia developed by ASKA in-house Research and Development.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com